Clara Türk, Chintan N. Koyani, Rui Adão, Simon Sedej, Francisco Vasques-Nóvoa, Tobias Pendl, Andreas Zirlik, Christian Mühlfeld, Lavinia Rech, Guido Kroemer, Akos Heinemann, Senka Ljubojevic-Holzer, Martina Auer, Wolfgang A. Linke, Julia Voglhuber, Daniel Scherr, Saša Frank, Johanna K. Freundt, Viktoria Trummer-Herbst, Julia Kargl, Stefan Kiechl, Sylvère Durand, Elías Herrero-Galán, Nathaly Anto-Michel, Adelino F. Leite-Moreira, Christina Brandenberger, Jorge Alegre-Cebollada, Albrecht Schmidt, Julia von Maltzahn, Frank Madeo, Julia Schipke, Michael Kasa, Andreas Prokesch, Mahmoud Abdellatif, Franziska Koser, Renate Schreiber, Sebastian J. Hofer, Fanny Aprahamian, André P. Lourenço, Tobias Eisenberg, Maria-Rosaria Pricolo, Peter P. Rainer, Dirk von Lewinski, Marcus Krüger, European Research Area Network on Cardiovascular Diseases (ERACVD), MINOTAUR consortium, Austrian Science Fundation, Agence Nationale de la Recherche (Francia), Bundesministerium für Bildung und Forschung, Instituto de Salud Carlos III, Portuguese Foundation for Science and Technology, European Society of Cardiology, Austrian Society of Cardiology, Ligue Nationale Contre le Cancer (Francia), Association de la Recherche Contre le Cancer (France), Association Ruban Rose, Chancelerie des universités de Paris, Fondation pour la recherche médicale (Francia), Institut National du Cancer, Institut Universitaire de France, Fondation Leducq, LabEx Immuno-Oncology, Ministerio de Ciencia e Innovación (España), Comunidad de Madrid (España), Austrian Research Promotion Agency, Pustertaler Verein zur Prävention von Herz-und Hirngefäßerkrankungen, Gesundheitsbezirk Bruneck, and Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent and intractable form of cardiac decompensation commonly associated with diastolic dysfunction. Here, we show that diastolic dysfunction in patients with HFpEF is associated with a cardiac deficit in nicotinamide adenine dinucleotide (NAD+). Elevating NAD+ by oral supplementation of its precursor, nicotinamide, improved diastolic dysfunction induced by aging (in 2-year-old C57BL/6J mice), hypertension (in Dahl salt-sensitive rats), or cardiometabolic syndrome (in ZSF1 obese rats). This effect was mediated partly through alleviated systemic comorbidities and enhanced myocardial bioenergetics. Simultaneously, nicotinamide directly improved cardiomyocyte passive stiffness and calcium-dependent active relaxation through increased deacetylation of titin and the sarcoplasmic reticulum calcium adenosine triphosphatase 2a, respectively. In a long-term human cohort study, high dietary intake of naturally occurring NAD+ precursors was associated with lower blood pressure and reduced risk of cardiac mortality. Collectively, these results suggest NAD+ precursors, and especially nicotinamide, as potential therapeutic agents to treat diastolic dysfunction and HFpEF in humans. This study was thankfully supported by the European Research Area Network on Cardiovascular Diseases (ERACVD) through the MINOTAUR consortium: S.S. (The Austrian Science Fund – FWF, I3301-B31), G.K. (Agence National de la Recherche – ANR), W.A.L. (Bundesministerium für Bildung und Forschung – BMBF), J.A.C. (Instituto de Salud Carlos III – ISCIII, AC16/00045) and A.L.M. (Portuguese Foundation for Science and Technology – FCT). M. Abdellatif acknowledges funding received from the European Society of Cardiology in form of an ESC Research Grant and from the Austrian Society of Cardiology (Präsidentenstipendium der ÖKG). The Austrian Science Fund supports S.F. (P27166-B23), A.P. (I3165, P29328-B26) and F.M. (P27893, P31727). S.S., J.V., F.M. and S.L.H. acknowledge support from the BioTechMed–Graz. G.K. is supported by the Ligue contre le Cancer (équipe labellisée); Association pour la recherche sur le cancer (ARC); Association Ruban Rose, Cancéropôle Ile-de-France; Chancelerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); Institut National du Cancer (INCa); Inserm (HTE); Inserm Transfert; Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology (ANR-18-IDEX-0001); the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM). J.A.C. acknowledges funding from the Ministerio de Ciencia e Innovación (MCIN) through grant BIO2017-83640-P (AEI/FEDER, UE) and the Comunidad de Madrid (consortium Tec4Bio-CM, S2018/ NMT-4443, FEDER). A.S. acknowledges support from BioPersMed Graz. S.K. receives funding from the Austrian Research Promotion Agency FFG (VASCage; Nr. 868624). The Bruneck Study was supported by the Pustertaler Verein zur Prävention von Herz-und Hirngefäßerkrankungen, Gesundheitsbezirk Bruneck, and the Assessorat für Gesundheit, Province of Bolzano, Italy. Sí